Systemic sclerosis & Raynaud's
Studying the Role of C5-Inhibition Therapy in Scleroderma Renal Crisis-Induced Thrombotic Microangiopathy – A Review of Literature
Study context
- Population
- Patients with SSc and scleroderma renal crisis (SRC) (including SRC-TMA) treated with Eculizumaball treated with Eculizumab
- Participants
- 17 patients
- Outcome
- Clinical (renal or hematologic) improvement with Eculizumab
Methodological detailsliterature search from inception to December 2022, Concomitant therapy: Angiotensin-converting enzyme inhibitors (ACE-I) 11/17 (64.7%), plasmapheresis 9/17 (52.9%), steroids 5/17 (29.4%), CYC 3/17 (17.6%), calcium channel blockers 3/17 (17.6%), RTX 3/17 (17.6%)
- Literature search from inception to December 2022
- Concomitant therapy: ACE-I 11/17 (64.7%), plasmapheresis 9/17 (52.9%), steroids 5/17 (29.4%), CYC 3/17 (17.6%), calcium channel blockers 3/17 (17.6%), RTX 3/17 (17.6%)
Pooled result
As reported in the abstract
Eculizumab
82.3%
14 of 17
Further pooled results
RRT required
- Patients requiring renal replacement therapy
- 11/17 (64.7%)
Concomitant therapies reported
- ACE-I
- 11/17 (64.7%)
- Plasmapheresis
- 9/17 (52.9%)
- Steroids
- 5/17 (29.4%)
- CYC
- 3/17 (17.6%)
- Calcium channel blockers
- 3/17 (17.6%)
- RTX
- 3/17 (17.6%)
Original publication
Studying the Role of C5-Inhibition Therapy in Scleroderma Renal Crisis-Induced Thrombotic Microangiopathy – A Review of Literature. Semin Arthritis Rheum. Published 22 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →